206 related articles for article (PubMed ID: 31165865)
21. Respiratory syncytial virus acute respiratory infection-associated hospitalizations in preterm Mexican infants: A cohort study.
Benítez-Guerra D; Piña-Flores C; Zamora-López M; Escalante-Padrón F; Lima-Rogel V; González-Ortiz AM; Guevara-Tovar M; Bernal-Silva S; Benito-Cruz B; Castillo-Martínez F; Martínez-Rodríguez LE; Ramírez-Ojeda V; Tello-Martínez N; Lomelí-Valdez R; Salto-Quintana J; Cadena-Mota S; Noyola DE
Influenza Other Respir Viruses; 2020 Mar; 14(2):182-188. PubMed ID: 31917902
[TBL] [Abstract][Full Text] [Related]
22. Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants.
Mejias A; Wu B; Tandon N; Chow W; Varma R; Franco E; Ramilo O
Pediatr Allergy Immunol; 2020 Jan; 31(1):47-56. PubMed ID: 31566811
[TBL] [Abstract][Full Text] [Related]
23. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
25. Chronic manifestations of respiratory syncytial virus infection in premature infants.
Greenough A; Broughton S
Pediatr Infect Dis J; 2005 Nov; 24(11 Suppl):S184-7, discussion S187-8. PubMed ID: 16378044
[TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
27. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.
Leader S; Kohlhase K
J Pediatr; 2003 Nov; 143(5 Suppl):S127-32. PubMed ID: 14615711
[TBL] [Abstract][Full Text] [Related]
28. RSV hospitalisation and healthcare utilisation in moderately prematurely born infants.
Shefali-Patel D; Paris MA; Watson F; Peacock JL; Campbell M; Greenough A
Eur J Pediatr; 2012 Jul; 171(7):1055-61. PubMed ID: 22302458
[TBL] [Abstract][Full Text] [Related]
29. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
O'Shea TM; Sevick MA; Givner LB
Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
[TBL] [Abstract][Full Text] [Related]
30. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
31. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases.
Paramore LC; Ciuryla V; Ciesla G; Liu L
Pharmacoeconomics; 2004; 22(5):275-84. PubMed ID: 15061677
[TBL] [Abstract][Full Text] [Related]
32. Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis.
Zhang S; Akmar LZ; Bailey F; Rath BA; Alchikh M; Schweiger B; Lucero MG; Nillos LT; Kyaw MH; Kieffer A; Tong S; Campbell H; Beutels P; Nair H;
J Infect Dis; 2020 Oct; 222(Suppl 7):S680-S687. PubMed ID: 32227101
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
34. A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
Suh M; Movva N; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S195-S212. PubMed ID: 35968876
[TBL] [Abstract][Full Text] [Related]
35. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018.
Demont C; Petrica N; Bardoulat I; Duret S; Watier L; Chosidow A; Lorrot M; Kieffer A; Lemaitre M
BMC Infect Dis; 2021 Aug; 21(1):730. PubMed ID: 34340679
[TBL] [Abstract][Full Text] [Related]
36. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
37. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D
Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717
[TBL] [Abstract][Full Text] [Related]
38. Respiratory syncytial virus infection in infants in rural Nepal.
Chu HY; Katz J; Tielsch J; Khatry SK; Shrestha L; LeClerq SC; Magaret A; Kuypers J; Steinhoff M; Englund JA
J Infect; 2016 Aug; 73(2):145-54. PubMed ID: 27241525
[TBL] [Abstract][Full Text] [Related]
39. Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
Mac S; Shi S; Millson B; Tehrani A; Eberg M; Myageri V; Langley JM; Simpson S
Vaccine; 2023 Aug; 41(35):5141-5149. PubMed ID: 37422377
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
